AbbVie (ABBV)
294.89
+4.10 (1.41%)
NYSE · Last Trade: Oct 31st, 3:54 AM EDT
News & Press Releases
AbbVie (ABBV) Q3 2026 Earnings Call Transcriptfool.com
Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance.
Via The Motley Fool · October 30, 2026
What AbbVie (ABBV) Said on Its Q3 Earnings Callmarketbeat.com
AbbVie (NYSE:ABBV) reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and neuroscience portfolios.
The company posted adjusted earnings per share of $3.82, $0.07 above the midpoi
Via MarketBeat · October 30, 2026
AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non...
Via StockStory · October 30, 2026
AbbVie (NYSE:ABBV) Q3 2026 Results In Line With Estimates as Guidance and Dividend Risechartmill.com
Via Chartmill · October 30, 2026
Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Liftingchartmill.com
Via Chartmill · October 22, 2026
AbbVie (ABBV) reports earnings tomorrow: what to expect
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what to expect. AbbVie beat analysts’ revenue expect...
Via StockStory · October 29, 2026
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buyfool.com
Despite its high price relative to earnings, AbbVie remains an attractive stock.
Via The Motley Fool · October 26, 2026
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomachmarketbeat.com
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Via MarketBeat · October 23, 2026
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizerfool.com
They definitely matter... up to a point.
Via The Motley Fool · October 22, 2026
Great News for AbbVie Stock Investorsfool.com
The company is gearing up for future major patent cliffs.
Via The Motley Fool · October 22, 2026
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?fool.com
AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.
Via The Motley Fool · October 21, 2026
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?fool.com
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
Via The Motley Fool · October 20, 2026
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.fool.com
This pharma leader has a history of outperforming during rising interest rates.
Via The Motley Fool · October 20, 2026
2 High-Flying Dividend Stocks to Buy and Hold for a Decadefool.com
They may just be getting started.
Via The Motley Fool · October 19, 2026
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive Itfool.com
Buffett has warned about "gambling" in the market.
Via The Motley Fool · October 19, 2026
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.fool.com
It was Griffin's biggest add for Citadel last quarter.
Via The Motley Fool · October 18, 2026
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cyclefool.com
Rising rates can expose dividend traps, but this Dividend King is built to keep paying.
Via The Motley Fool · October 17, 2026
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buysfool.com
These funds can help you weather any storm that might be on the way.
Via The Motley Fool · October 17, 2026
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividendsfool.com
You'd need to invest over $200,000 in the pharma leader at its current price.
Via The Motley Fool · October 16, 2026
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?fool.com
AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
Via The Motley Fool · October 15, 2026
Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaqchartmill.com
Via Chartmill · October 15, 2026
Top S&P500 movers in Wednesday's sessionchartmill.com
Via Chartmill · October 14, 2026
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Via Chartmill · October 14, 2026
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via StockStory · October 14, 2026
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?fool.com
One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation.
Via The Motley Fool · October 13, 2026